The Mitral Valve Disease Market valued for $2.44 Billion in 2021 and is estimated to reach $5.69 Billion by 2031, exhibiting a CAGR of 8.8% from 2022 to 2031.
Mitral valve is an essential component of the heart's circulatory system that is located on the left side of the heart between the left atrium and left ventricle. It is responsible for regulating the flow of blood from the left atrium into the left ventricle. When the mitral valve is diseased or damaged, it can lead to a range of problems that can affect the heart's ability to pump blood efficiently. Common mitral valve conditions include mitral valve stenosis, mitral valve prolapse, and mitral valve regurgitation.
For example, if the valve is narrowed, the amount of blood that can flow from the left atrium into the left ventricle is reduced, which can cause the left atrium to enlarge, thus increasing the pressure in lungs. These conditions can lead to symptoms such as shortness of breath, fatigue, and chest pain. In some cases, the valve is not able to close properly, causing the blood to flow back into the atrium, which can lead to similar symptoms. In both cases, treatment may involve medication or therapeutics to manage symptoms, but in severe cases, surgery may be required to repair or replace the valve. In some cases of mitral valve regurgitation, cardiac resynchronization therapy may be used to treat the condition.
The major factor driving the growth of mitral valve disease market is increase in prevalence of mitral valve diseases. Alarming increase has been witnessed in the number of patients diagnosed with mitral valve diseases such as mitral regurgitation, mitral prolapse, and mitral stenosis. For instance, Journal of Clinical Medicine 2022 stated that mitral regurgitation is the second most common valvular heart disease in Europe and the most common in the U.S., with a prevalence of 9.3% in the population aged over 75 years. Thus, rise in prevalence of mitral valve diseases such as mitral stenosis, mitral prolapse, and mitral regurgitation escalates the demand for various treatment options, including therapeutics, repair, and replacement surgeries and cardiac synchronization therapy, which, in turn, contributes toward the growth of the global mitral valve disease market.
In addition, technological advancements have played a significant role in driving the market growth in recent years. As the prevalence of mitral valve diseases rises, the demand for better treatment options that can provide improved outcomes and reduced recovery times increases simultaneously. One of the most significant technological advancements in this field is the development of minimally invasive techniques such as transcatheter mitral valve replacement (TMVR). This technique involves replacing the diseased valve with an artificial valve through a small incision in the groin or chest. This offers several advantages over traditional open-heart surgery, such as reduced recovery time and lower risk of complications. Thus, huge demand for technologically advanced mitral valve treatment devices in the healthcare sector fuels the growth of the market.
Furthermore, surge in geriatric population drives the demand for mitral valve disease treatments around the globe, owing to the fact that aged individuals are highly susceptible to mitral valve diseases. Moreover, with growing age , the valve can be damaged or weakened, making it more prone to malfunction. In addition, rise in risk factors such as high blood pressure and obesity can increase the risk of developing mitral valve disease, which is anticipated to foster the growth of mitral valve disease market.
However, the cost of mitral valve treatment procedures such as repair, replacement, and cardiac synchronization therapy is significantly high, which acts as a barrier for the market growth. In addition, low awareness among the population in underdeveloped countries regarding the available treatments hinders the market growth. Moreover, stringent regulations by the governing bodies for the development and launching of mitral valve treatment products may indeed be a hindrance to market growth.
On the contrary, increase in demand for advanced healthcare services, rise in awareness of mitral valve treatment medications & procedures, and government investments in healthcare infrastructure are expected to provide remunerative opportunities for the expansion of the market during the forecast period. Governments in Asia-Pacific and LAMEA are substantially investing in the development of healthcare infrastructure and increasing the access to healthcare services, which notably drive the growth of the mitral valve disease market.
The global mitral valve disease market is segmented into treatment type, indication, end user, and region. On the basis of treatment type, the market is fragmented into mitral valve repair, mitral valve replacement, cardiac resynchronization therapy (CRT), and mitral valve therapeutics. The mitral valve replacement segment is further bifurcated into mechanical valves and biological valves (bioprosthetic tissue). On the other hand, the mitral valve therapeutics segment is subdivided into beta blockers, diuretics, anticoagulants, and others.
Depending on indication, the market is fragmented into mitral valve stenosis, mitral valve prolapse, and mitral valve regurgitation. Furthermore, mitral valve regurgitation segment is bifurcated into primary (degenerative) mitral valve regurgitation and secondary (functional) mitral valve regurgitation. By end user, the market is segregated into hospitals, ambulatory surgical centers, and others.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The major players that operate in the mitral valve disease market include Valcare Medical, Affluent Medical, Abbott Laboratories, Corcym UK Limited, Edwards Lifesciences Corporation, Medtronic Plc., ShockWave Medical, Inc., Artivion, Inc., Labcor Laboratorios Ltda, Braile Biomédica, Zydus Lifesciences Limited, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Bayer AG, and Novartis AG.
Mitral valve is an essential component of the heart's circulatory system that is located on the left side of the heart between the left atrium and left ventricle. It is responsible for regulating the flow of blood from the left atrium into the left ventricle. When the mitral valve is diseased or damaged, it can lead to a range of problems that can affect the heart's ability to pump blood efficiently. Common mitral valve conditions include mitral valve stenosis, mitral valve prolapse, and mitral valve regurgitation.
For example, if the valve is narrowed, the amount of blood that can flow from the left atrium into the left ventricle is reduced, which can cause the left atrium to enlarge, thus increasing the pressure in lungs. These conditions can lead to symptoms such as shortness of breath, fatigue, and chest pain. In some cases, the valve is not able to close properly, causing the blood to flow back into the atrium, which can lead to similar symptoms. In both cases, treatment may involve medication or therapeutics to manage symptoms, but in severe cases, surgery may be required to repair or replace the valve. In some cases of mitral valve regurgitation, cardiac resynchronization therapy may be used to treat the condition.
The major factor driving the growth of mitral valve disease market is increase in prevalence of mitral valve diseases. Alarming increase has been witnessed in the number of patients diagnosed with mitral valve diseases such as mitral regurgitation, mitral prolapse, and mitral stenosis. For instance, Journal of Clinical Medicine 2022 stated that mitral regurgitation is the second most common valvular heart disease in Europe and the most common in the U.S., with a prevalence of 9.3% in the population aged over 75 years. Thus, rise in prevalence of mitral valve diseases such as mitral stenosis, mitral prolapse, and mitral regurgitation escalates the demand for various treatment options, including therapeutics, repair, and replacement surgeries and cardiac synchronization therapy, which, in turn, contributes toward the growth of the global mitral valve disease market.
In addition, technological advancements have played a significant role in driving the market growth in recent years. As the prevalence of mitral valve diseases rises, the demand for better treatment options that can provide improved outcomes and reduced recovery times increases simultaneously. One of the most significant technological advancements in this field is the development of minimally invasive techniques such as transcatheter mitral valve replacement (TMVR). This technique involves replacing the diseased valve with an artificial valve through a small incision in the groin or chest. This offers several advantages over traditional open-heart surgery, such as reduced recovery time and lower risk of complications. Thus, huge demand for technologically advanced mitral valve treatment devices in the healthcare sector fuels the growth of the market.
Furthermore, surge in geriatric population drives the demand for mitral valve disease treatments around the globe, owing to the fact that aged individuals are highly susceptible to mitral valve diseases. Moreover, with growing age , the valve can be damaged or weakened, making it more prone to malfunction. In addition, rise in risk factors such as high blood pressure and obesity can increase the risk of developing mitral valve disease, which is anticipated to foster the growth of mitral valve disease market.
However, the cost of mitral valve treatment procedures such as repair, replacement, and cardiac synchronization therapy is significantly high, which acts as a barrier for the market growth. In addition, low awareness among the population in underdeveloped countries regarding the available treatments hinders the market growth. Moreover, stringent regulations by the governing bodies for the development and launching of mitral valve treatment products may indeed be a hindrance to market growth.
On the contrary, increase in demand for advanced healthcare services, rise in awareness of mitral valve treatment medications & procedures, and government investments in healthcare infrastructure are expected to provide remunerative opportunities for the expansion of the market during the forecast period. Governments in Asia-Pacific and LAMEA are substantially investing in the development of healthcare infrastructure and increasing the access to healthcare services, which notably drive the growth of the mitral valve disease market.
The global mitral valve disease market is segmented into treatment type, indication, end user, and region. On the basis of treatment type, the market is fragmented into mitral valve repair, mitral valve replacement, cardiac resynchronization therapy (CRT), and mitral valve therapeutics. The mitral valve replacement segment is further bifurcated into mechanical valves and biological valves (bioprosthetic tissue). On the other hand, the mitral valve therapeutics segment is subdivided into beta blockers, diuretics, anticoagulants, and others.
Depending on indication, the market is fragmented into mitral valve stenosis, mitral valve prolapse, and mitral valve regurgitation. Furthermore, mitral valve regurgitation segment is bifurcated into primary (degenerative) mitral valve regurgitation and secondary (functional) mitral valve regurgitation. By end user, the market is segregated into hospitals, ambulatory surgical centers, and others.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The major players that operate in the mitral valve disease market include Valcare Medical, Affluent Medical, Abbott Laboratories, Corcym UK Limited, Edwards Lifesciences Corporation, Medtronic Plc., ShockWave Medical, Inc., Artivion, Inc., Labcor Laboratorios Ltda, Braile Biomédica, Zydus Lifesciences Limited, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Bayer AG, and Novartis AG.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the mitral valve disease market analysis from 2021 to 2031 to identify the prevailing mitral valve disease market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the mitral valve disease market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global mitral valve disease market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Treatment Type
- Mitral Valve Repair
- Mitral Valve Replacement
- Product Type
- Mechanical Valves
- Biological Valves
- Cardiac Resynchronization Therapy
- Mitral Valve Therapeutics
- Drug Class
- Beta blockers
- Diuretics
- Anticoagulants
- Others
By Indication
- Mitral Valve Stenosis
- Mitral Valve Prolapse
- Mitral Valve Regurgitation
- Type
- Primary Mitral Valve Regurgitation
- Secondary Mitral Valve Regurgitation
By End User
- Hospitals
- Ambulatory Surgical Centers
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Bayer AG
- Zydus Lifesciences Limited
- Affluent Medical
- Artivion, Inc.
- Valcare Medical
- Corcym UK Limited
- Pfizer Inc.
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Medtronic plc
- ShockWave Medical, Inc.
- Braile Biomedica
- Abbott Laboratories
- Labcor Laboratorios Ltda
- Edwards Lifesciences Corporation
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: MITRAL VALVE DISEASE MARKET, BY TREATMENT TYPE
CHAPTER 5: MITRAL VALVE DISEASE MARKET, BY INDICATION
CHAPTER 6: MITRAL VALVE DISEASE MARKET, BY END USER
CHAPTER 7: MITRAL VALVE DISEASE MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Companies Mentioned
- Bayer AG
- Zydus Lifesciences Limited
- Affluent Medical
- Artivion, Inc.
- Valcare Medical
- Corcym UK Limited
- Pfizer Inc.
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Medtronic plc
- ShockWave Medical, Inc.
- Braile Biomedica
- Abbott Laboratories
- Labcor Laboratorios Ltda
- Edwards Lifesciences Corporation
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
